Wegovy

Wegovy is a prescription weight-loss drug developed by Novo Nordisk, a Danish pharmaceutical company. The company has been a pioneer in the growth of weight-loss treatments. Recently, Novo Nordisk predicted a sharp drop in revenues for 2026 due to increased competition and lower US weight-loss drug prices. However, this is overshadowed by the recent approval of Wegovy's pill form by the US FDA, marking a new era for weight-loss drugs. This development has significant implications for the treatment of obesity, particularly with the increasing availability of over-the-counter sellers in Hong Kong and potential counterfeit pills flooding Britain. The approval of Wegovy's pill form is also seen as a convenient option for patients who prefer oral medication over injections.